The Oncode Oncology Bridge Fund helps bring innovative cancer research from the lab to real-world impact. This fund supports the creation and growth of spin-off companies founded on discoveries by Oncode Institute researchers, speeding up new treatments for patients and benefits for society.
About the Fund
Oncode Institute created the Oncology Bridge Fund to help promising research turn into tangible solutions for people with cancer. The fund provides pre-seed and seed investments, giving researchers the financial foundation they need to bring their ideas to the market.
Oncode B.V.
Oncode B.V., a wholly owned subsidiary of Oncode Institute, manages all operational aspects of the Bridge Fund. Since its launch in September 2018, Oncode B.V. has sourced and evaluated investment opportunities, conducted due diligence, negotiated agreements, monitored company progress, and managed the overall investment portfolio. The Supervisory Board, which mirrors the Oncode Institute’s board, oversees strategy and governance to ensure the fund’s long-term goals are met.
Investment Criteria
To make the greatest impact, the Bridge Fund invests in new companies that are founded by Oncode Institute researchers or are based on our technology. Enterprises must focus on oncology and show clear potential for long-term viability. Each proposal is reviewed for its business plan, market focus, funding requirements, and go-to-market strategy. Our team is ready to help researchers shape their ideas to meet these requirements and move them closer to success.
Opportunities to Co-invest
We believe that progress is faster together. That’s why we welcome co-investment from industry and venture partners. Our process for investment is transparent and thorough, starting with an initial assessment, followed by detailed due diligence, structuring agreements, and final approval from our Investment Advisory Committee. When terms are agreed, successful companies receive a convertible loan or investment agreement to help them take the next step.
If you are interested in joining us as a co-investor, please reach out. We are happy to discuss the possibilities with you.
Our Portfolio Companies
The Bridge Fund has already supported several ambitious companies, including Immagene, Cyclomics, Laigo Bio, Oncosence, Single Cell Discoveries, Simmunext Biotherapeutics, and Cell Control. These ventures are advancing new solutions in oncology, each inspired by Oncode Institute research.
Contact
Would you like to learn more about the Bridge Fund, our portfolio companies, or opportunities to co-invest? Please contact our fund manager, Shobhit Dhawan. We look forward to helping you turn innovation into impact.
Shobhit Dhawan
Shobhit is the Fund Manager of Oncode Oncology Bridge Fund. Prior to joining Oncode Bridge Fund, he was an early stage investor at UvA/AMC Ventures for 4 years, where he made investments in tech and life science spin offs from the two institutions. Before UvA ventures, Shobhit supported early stage ventures with fundraising and business strategy at ACE incubator in Amsterdam. He trained as a pharmacologist at the University of Oxford and started his drug discovery career at Pfizer UK. Shobhit holds a PhD in immunology from the University of Amsterdam.